Scarica l'app Stockscreener
31.90
0.63%
0.20
Dopo l'orario di chiusura:
32.50
0.60
+1.88%
Precedente Chiudi:
$31.70
Aprire:
$31.78
Volume 24 ore:
965.11K
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.47B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-11.64
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-1.12%
1M Prestazione:
+5.32%
6M Prestazione:
-18.93%
1 anno Prestazione:
-12.00%
Intervallo 1D:
$31.22
$32.59
Intervallo di 1 settimana:
$31.22
$33.46
Portata 52W:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
31.90 | 2.47B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - marketscreener.com
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 03 - marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Squarepoint Ops LLC - Defense World
xenon pharmaceuticals reports shareholder voting results By Investing.com - Investing.com South Africa
xenon pharmaceuticals reports shareholder voting results - Investing.com
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon to Present at the Goldman Sachs 46th Annual Global Healthc - GuruFocus
Xenon Pharmaceuticals to Present at Global Healthcare Conference - TipRanks
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | XENE Stock News - GuruFocus
Xenon CEO to Update Investors on Breakthrough Epilepsy Drug at Goldman Sachs Healthcare Conference - Stock Titan
Stock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Analyzing Xenon Pharmaceuticals (NASDAQ:XENE) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Lis - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Awards $1.5M in Stock Options to 7 New Hires Under Nasdaq Rule - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE - Defense World
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals at RBC Capital Markets: Strategic Insights on Ezetucalmer - Investing.com India
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for XENE - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GANNON STEVEN | Director |
May 14 '25 |
Option Exercise |
12.57 |
5,144 |
64,660 |
7,144 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):